Projects per year
Abstract
Despite intensive efforts to optimize the process, reprogramming differentiated cells to induced pluripotent stem cells (iPSCs) remains inefficient. The most common combination of transcription factors employed comprises OCT4, KLF4, SOX2, and MYC (OKSM). If MYC is omitted (OKS), reprogramming efficiency is reduced further. Cells must overcome several obstacles to reach the pluripotent state, one of which is apoptosis. To directly determine how extensively apoptosis limits reprogramming, we exploited mouse embryonic fibroblasts (MEFs) lacking the two essential mediators of apoptosis, BAK and BAX. Our results show that reprogramming is enhanced in MEFs deficient in BAK and BAX, but only when MYC is part of the reprogramming cocktail. Thus, the propensity for Myc overexpression to elicit apoptosis creates a significant roadblock to reprogramming under OKSM conditions. Our results suggest that blocking apoptosis during reprogramming may enhance the derivation of iPSCs for research and therapeutic purposes. In this article, Heath, van Delft, and colleagues show that mitochondrial apoptosis limits OKSM-mediated reprogramming of MEFs. Not only is reprogramming of MEFs lacking the two essential mediators of mitochondrial apoptosis, BAK and BAX, significantly enhanced in the presence of MYC, but reprogramming in these conditions does not compromise genome integrity.
| Original language | English |
|---|---|
| Pages (from-to) | 331-338 |
| Number of pages | 8 |
| Journal | Stem Cell Reports |
| Volume | 10 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - 13 Feb 2018 |
Keywords
- BAK
- BAX
- induced pluripotent stem cells
- mitochondrial apoptosis
- mouse embryonic fibroblasts: reprogramming
- MYC
- p53
Projects
- 2 Finished
-
Alternative splicing- a regulatory mechanism determining self-renewal and pluripotency of ES and iPS cells
Anko, M.-L. (Primary Chief Investigator (PCI))
NHMRC - National Health and Medical Research Council (Australia)
1/01/13 → 31/12/15
Project: Research
-
Colorectal cancer - molecular basis to targeted therapeutics
Lackmann, M. (Primary Chief Investigator (PCI)), Burgess, A. W. (Partner Investigator (PI)), Caruso, F. (Partner Investigator (PI)), Ernst, M. R. W. (Partner Investigator (PI)), Garrett, T. (Partner Investigator (PI)), Heath, J. (Partner Investigator (PI)), Ramsey, R. (Partner Investigator (PI)), Scott, A. (Partner Investigator (PI)) & Simpson, R. J. (Partner Investigator (PI))
NHMRC - National Health and Medical Research Council (Australia)
1/09/09 → 31/12/13
Project: Research